|
|
|
|
| Go to your Industry Sector |
|
|
|
|
|
|
| |
|
|
|
Informa Life Sciences
|
|
| 9th Annual Protein Kinases Congress |
|
|
|
|
|
|
| |
|
 |
|
|
|
|
| |
Wed 17 Mar 2010
- Thu 18 Mar 2010
MARITIM proArte Hotel, Berlin, Germany
|
|
|
|
Don’t let your most promising drug be shelved in clinical trials!
Join us to discover potential toxicities in early stage discovery and plan ahead for success at Informa Life Sciences’ 2010 Protein Kinases Congress - Brand NEW sessions for 2010 include:
P Inhibitor selectivity: Optimising your kinase based therapeutics: Hear from Bayer Schering Pharma, Novartis and Almirall on how they have approached where to draw he line on selectivity
P Progressing kinase inhibitors into clinical trials: Gaining success beyond phase 1 - Essential insights on improving preclinical and clinical translation and ensuring your compound has the comprehensive safety profile it needs to progress
P Filling the R&D pipeline: Uncovering novel kinase targets and pathways. This session will highlight how by investing time into looking into the kinome new realistic opportunities can be discovered for future development
Do not miss 2010’s only European forum covering the discovery and development of Protein Kinases and how you can successfully progress these products into clinical trials – download the brochure today!
|
Don't Miss
Discover where protein kinases are making a difference in the pharmaceutical industry through case study presentations from:
Peter Drueckes, Teamhead Kinase Profiling, Novartis Pharma, Switzerland
Thomas Zollner, Head - Transgenic & Spec. In-vivo-Pharmacology, Bayer Schering Pharma AG, Germany
Juan M. Domínguez, Drug Discovery Head, Noscira, Spain
Helen Boyd, HTS Team Leader, Pfizer Global Research and Development, UK
Bernd Riedl, Director, Medicinal Chemistry, Bayer Schering Pharma, Germany
Jeff Ecsedy, Millennium: The Takeda Oncology Co., United States
Oliver Plettenburg, Senior Research Scientist, Sanofi-Aventis, Germany
Kerstin Rohr, Biomarker/Experimental Medicine Scientist, F. Hoffman-La Roche, Switzerland
Jürgen Moll, Director of Cell Biology, Nerviano Medical Sciences Srl., Italy
Michael Teifel, Director - Head of Preclinical Development , Æterna Zentaris, Germany
Stefan Bartoschek, Senior Scientist, Sanofi-Aventis GmbH, Germany
Adelina Orellana, Senior Research Scientist, Biological Reagents Assay Development Screening, Almirall, Spain
|
|
Pre-Conference workshops | Tuesday 16 March 2010
Exploring Protein-Protein Interactions as Drug Targets
Post-Conference Workshops | Friday 19 March 2010
Allosteric Modulation as a successful drug target
Structure-base approaches to drug design
For more information on these workshops, please click here.
For further details on these and other workshops, download the 2010 brochure.
Exhibit at the conference or become a sponsor!
The joint congress will be accompanied by a large exhibition hall. There are a wide range of sponsorship opportunities available. In 2009 speaking positions were quickly sold out and the exhibition space was fully booked. To make an early enquiry about sponsorship and exhibition at the meeting please contact Ben Edwards at ben.edwards@informa.com or visit www.informa-ls.com/targetsandtools for further information.
|
|
|
|
|
|
|
|
|
|